This is a preliminary report on a plan at Scripps to explore the role genes play in longevity and disease in the elderly, but from a different angle to those studies which preceded it. While previous studies have identified genetic markers which predispose the elderly to specific age-related diseases, this study of the genome will focus on genetic variations which either hinder activity of harmful disease factors or serve as more efficient protective factors. A second project, ongoing at Albert Einstein and using microarrays, will be coordinated with this one. This should enhance the reliability of their findings. The implications are significant--it is conceivable that pharmaceuticals could be developed that would control the effect of these genetic variations--a "brave new world."